These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 9865302)

  • 101. Mycophenolate mofetil conversion or addition in patients with chronic progressive deterioration of renal allograft function.
    Altaca G; Berber I; Aydin C; Yigit B; Aydin M; Titiz I
    Transplant Proc; 2001; 33(7-8):3248-9. PubMed ID: 11750391
    [No Abstract]   [Full Text] [Related]  

  • 102. Progress with cyclosporine-sparing regimens.
    Grinyó JM
    Transplant Proc; 1999 Dec; 31(8A):11S-16S. PubMed ID: 10616555
    [No Abstract]   [Full Text] [Related]  

  • 103. A 3-hour postdose cyclosporine level during the first week after kidney transplantation predicts acute rejection and cyclosporine nephrotoxicity more accurately than trough levels.
    Mahalati K; Belitsky P; West K; Kiberd B; MacDonald A; McAlister V; Lawen J
    Transplant Proc; 2000 Jun; 32(4):786-7. PubMed ID: 10856585
    [No Abstract]   [Full Text] [Related]  

  • 104. Mycophenolate mofetil without antibody induction in pediatric renal transplantation.
    Ojogho ON; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W
    Transplant Proc; 2002 Aug; 34(5):1953-4. PubMed ID: 12176641
    [No Abstract]   [Full Text] [Related]  

  • 105. Induction therapy with bolus ATG increases cyclosporine sensitivity in renal transplant recipients.
    Varghese Z; Abudher MN; Fernando ON; Moorhead JF
    Transplant Proc; 2001 May; 33(3):2251-3. PubMed ID: 11377518
    [No Abstract]   [Full Text] [Related]  

  • 106. Evaluation of immunosuppressive induction regimens in renal transplantation. Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1998 Dec; 30(8):4029-30. PubMed ID: 9865286
    [No Abstract]   [Full Text] [Related]  

  • 107. Cyclosporine: has it made a difference between using HLA or not? A comparative study between patients with and without HLA matching.
    Juarez F; Barrios Y; Cano L; Chavez E; Camacho R; Gomez A; Maciel M; Borjon S; Limones M; Peniche L
    Transplant Proc; 1998 Aug; 30(5):1744-5. PubMed ID: 9723263
    [No Abstract]   [Full Text] [Related]  

  • 108. Drug regimens affect cadaveric kidney graft survival.
    Kauffman HM; Cherikh WS; Delmonico FL
    Transplant Proc; 2001; 33(1-2):1029-30. PubMed ID: 11267176
    [No Abstract]   [Full Text] [Related]  

  • 109. Pharmacokinetic study of mycophenolate mofetil in Asian renal transplant recipients.
    Yeung S; Tong KL; Tsang WK; Chan HW; Chan AY
    Transplant Proc; 2000 Nov; 32(7):1753-4. PubMed ID: 11119920
    [No Abstract]   [Full Text] [Related]  

  • 110. Effects of mycophenolate mofetil and azathioprine on the erythropoietin production in renal transplant recipients.
    Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Risaliti A; Baccarani U; Sainz M; Mioni G
    Transplant Proc; 2001; 33(7-8):3253-5. PubMed ID: 11750393
    [No Abstract]   [Full Text] [Related]  

  • 111. Neoral drug monitoring in stable kidney allotransplant recipients: C(0) versus C(2).
    Lukaschek J; Hofmann J; Aerne D; Ambühl P; Kistler T; Knoflach A; Pei P; Binswanger U
    Transplant Proc; 2001; 33(7-8):3104-5. PubMed ID: 11750334
    [No Abstract]   [Full Text] [Related]  

  • 112. Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients.
    Aigrain EJ; Shaghaghi EK; Baudouin V; Popon M; Loirat C
    Transplant Proc; 2000 Mar; 32(2):388-90. PubMed ID: 10715449
    [No Abstract]   [Full Text] [Related]  

  • 113. Prospective randomized pilot study of steroid withdrawal with mycophenolate mofetil in long-term cyclosporine-treated patients: 4-year follow-up.
    Budde K; Geissler S; Hallebach G; Waiser J; Fritsche L; Böhler T; Neumayer HH
    Transplant Proc; 2002 Aug; 34(5):1703-5. PubMed ID: 12176544
    [No Abstract]   [Full Text] [Related]  

  • 114. Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.
    Torras J; Figueras J; Lama C; Fabregat J; Ramos E; Rafecas A; Gil-Vernet S; Pares D; Busquets J; Jaurrieta E
    Transplant Proc; 1999 Sep; 31(6):2430. PubMed ID: 10500656
    [No Abstract]   [Full Text] [Related]  

  • 115. Conversion to mycophenolate mofetil for chronic progressive deterioration of renal allograft function: first clinical experiences in 44 patients.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Morgera S; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Jun; 30(4):1190-1. PubMed ID: 9636481
    [No Abstract]   [Full Text] [Related]  

  • 116. HLA-identical renal transplant recipients: immunosuppression, long-term complications, and survival.
    Peddi VR; Weiskittel P; Alexander JW; Woodle ES; First MR
    Transplant Proc; 2001; 33(7-8):3411-3. PubMed ID: 11750460
    [No Abstract]   [Full Text] [Related]  

  • 117. Mycophenolate mofetil-induced hyperbilirubinemia in renal transplant recipients.
    Chueh SC; Huang CY; Lai MK
    Transplant Proc; 2000 Nov; 32(7):1901-2. PubMed ID: 11119992
    [No Abstract]   [Full Text] [Related]  

  • 118. Area under the curve of Neoral and chronic use of mycophenolate mofetil.
    Rial M; Guardia O; Greco G; Argento J; Casadei D
    Transplant Proc; 1998 Jun; 30(4):1195-6. PubMed ID: 9636484
    [No Abstract]   [Full Text] [Related]  

  • 119. Use of mycophenolate mofetil in renal transplant patients with cyclosporin toxicity.
    Shaheen FA; Sheikh IA
    Transplant Proc; 1999 Dec; 31(8):3294. PubMed ID: 10616481
    [No Abstract]   [Full Text] [Related]  

  • 120. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients.
    Bryan CF; Nelson PW; Shield CF; Warady BA; Winklhofer FT; Murillo D; Wakefield MR
    Am J Transplant; 2007 May; 7(5):1181-4. PubMed ID: 17359511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.